Method for treatment and diagnosis of IL-5 mediated disorders
AssigneeSmithKline Beecham Corporation
InventorsEdward Robert Appelbaum, Richard Murray Cook
Life of this patent
Estimating the term…
Abstract
The present invention relates to treatment and diagnosis of conditions mediated by IL-5 and excess eosinophil production, and more specifically to mAbs and other altered antibodies such as Fabs, chimeric, human and humanized antibodies that do not block binding of human IL-5 to the .alpha.-chain of the human IL-5 receptor.
Claims10
An improved method for treating interleukin-5(IL-5) mediated conditions associated with excess eosinophil productions wherein the improvement comprises the step of:
- administering a neutralizing monoclonal antibody for human IL-5 which does not block binding of human IL-5 to the .alpha.-chain of the human IL-5 receptor and which binds both free and receptor complexed IL-5 in an amount effective to ameliorate the symptoms of said conditions.
A method to assess the presence or absence of a human IL-5 soluble receptor .alpha.-chain/human IL-5 complex in a human which comprises:
- obtaining a sample of biological fluid from a patient and allowing a monoclonal antibody for human IL-5 which does not block binding of human IL-5 to the .alpha.-chain of the human IL-5 receptor to come in contact with such sample under conditions such that a human IL-5 soluble receptor .alpha.-chain/human IL-5/monoclonal antibody complex can form;
- and
- detecting the presence or absence of said human IL-5 soluble receptor .alpha.-chain/human IL-5/ monoclonal antibody complex.
A method of screening compounds to identify those compounds which antagonize binding of a human IL-5 soluble receptor .alpha.-chain/human IL-5 complex to a human IL-5 receptor .beta.-chain which method comprises:
- contacting the human IL-5 receptor .alpha.-chain with at least one candidate compound under conditions to permit binding to the receptor, and
- identifying those candidate compounds that antagonize binding of a human IL-5 soluble receptor .alpha.-chain/human IL-5 complex.
A method of screening compounds to identify those compounds which antagonize binding of a human IL-5 soluble receptor .alpha.-chain / human IL-5/monoclonal antibody for human IL-5 which does not block binding of human IL-5 to the .alpha.-chain of the human IL-5 receptor complex to a human IL-5 receptor .beta.-chain, which method comprises:
- contacting the human IL-5 receptor .beta.-chain with at least one candidate compound under conditions to permit binding to the IL-5 receptor .beta.-chain;
- and
- identifying those candidate compounds that antagonize binding of said receptor/IL-5/antibody complex to the IL-5 receptor .beta.-chain.
Dependencies are inferred from the claim text.